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Context: Prevalence data are important for assessing the burden of
disease on the health care system; data on pituitary adenoma prev-
alence are very scarce.
Objective: The objective of the study was to measure the prevalence
of clinically relevant pituitary adenomas in awell-defined population.
Design: This was a cross-sectional, intensive, case-finding study per-
formed in three regions of the province of Lie`ge, Belgium, to measure
pituitary adenoma prevalence as of September 30, 2005.
Setting: The study was conducted in specialist and general medical
practitioner patient populations, referral hospitals, and investiga-
tional centers.
Methods: Three demographically and geographically distinct dis-
tricts of the province of Lie`ge were delineated precisely using postal
codes. Medical practitioners in these districts were recruited, and
patients with pituitary adenomas under their care were identified.
Diagnoses were confirmed after retrieval of clinical, hormonal, ra-
diological, and pathological data; full demographic and therapeutic
follow-up data were collected in all cases.
Results: Sixty-eight patients with clinically relevant pituitary ade-
nomas were identified in a population of 71,972 individuals; themean
( SD) prevalence was 94  19.3 cases per 100,000 population (95%
confidence interval, 72.2 to 115.8). The group was 67.6% female and
hadameanage at diagnosis of 40.3 yr; 42.6%hadmacroadenomas and
55.9% underwent surgery. Prolactinomas comprised 66% of the
group, with the rest having nonsecreting tumors (14.7%), soma-
totropinomas (13.2%), or Cushing’s disease (5.9%); 20.6% had
hypopituitarism.
Conclusion: The prevalence of pituitary adenomas in the study pop-
ulation (one case in 1064 individuals) was more than 3.5–5 times that
previously reported. This increased prevalence may have important
implications when prioritizing funding for research and treatment of
pituitary adenomas. (J Clin Endocrinol Metab 91: 4769–4775,
2006)
TUMOR PREVALENCE DATA are important for the es-timation of disease burden in populations and are often
used to calculate health care resource distributionwithin and
among clinical specialties. Existing data on the prevalence of
pituitary adenomas are discordant. Estimates from cancer
registries suggest that pituitary adenomas are uncommon,
particularly as compared with solid tumors such as breast,
lung, and colon cancers (1). In contrast, a comprehensive
metaanalysis of data from autopsy and radiological studies
indicates that pituitary tumors may be present in as many as
one in every six people (2). The inclusion of a sizable number
of small nonclinically relevant adenomas (incidentalomas) in
autopsy/radiological series probably accounts for a propor-
tion of the reported high prevalence, but as noted by Ezzat
et al. (2), many tumors from autopsy series are immunohis-
tochemically positive for pituitary hormones. Existing epi-
demiological data suggest that the incidence of pituitary
adenomas is rising, although it is difficult to determine
whether this is due to widespread access to magnetic reso-
nance imaging (MRI) and accurate biochemical testing, lead-
ing to improved recognition of clinically relevant pituitary
tumors (3). The uncertainty regarding the true prevalence of
clinically active pituitary adenomas led us to undertake an
intensive, cross-sectional epidemiological study of the cur-
rent prevalence of pituitary adenomas in a tightly defined
geographical area in Lie`ge, Belgium.
Patients and Methods
Study setting
Three separate geographic areas within the province of Lie`ge were
chosen for the study. The definition of prevalence for this study was that
generally used in cancer epidemiology: “prevalence is the number
and/or proportion of people with a past or present diagnosis of a
pituitary adenoma within a well-defined population at a fixed point in
time” (4). To reflect the diverse characteristics of the Belgian population
densities, the individual areas had specific demographic profiles: rural
(Soiron), suburban (Oupeye), and urban (Ans-Alleur), and all had a
similar number of inhabitants. To define the geographical boundaries of
each study region precisely, Belgian post office code designations were
used. Study district I, Soiron (postal codes 4860, 4861, 4870, 4877), con-
sisted of a population of 21,024 inhabitants; study district II, Oupeye
(postal codes 4680, 4681, 4682, 4683, 4684), had 23,598 inhabitants; and
study district III, Ans-Alleur (postal codes 4430, 4431, 4432), had 27,350
inhabitants (Fig. 1). The total population for the study was 71,972. Only
living individuals residing within the predetermined geographic
boundaries on a specific day were deemed eligible for inclusion in the
study. The defined date for validating whether patients were alive and
were residing in one of the postal code-defined areas was September 30,
2005. The study protocol was approved by the Ethics Committee of the
University of Lie`ge (Lie`ge, Belgium) and was performed under the
tenets of the Declaration of Helsinki and its subsequent amendments.
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Within the three defined study areas, all general practitioners and
relevant specialists (endocrinologists, gynecologists, neurosurgeons)
working in public/private practice were identified. Subsequently, the
identified medical practitioners were contacted directly to recruit them
to the study, and each received a simple case report form containing
headings for demographic and disease characteristic criteria. Educa-
tionalmeetings on the topic of the clinical recognition, investigation, and
management of patients with pituitary tumors were organized for med-
ical practitioners within each study area; attendees received information
regarding the design and purpose of the present epidemiological study.
The proportion of medical practitioners within the study sample sites
that participated in the study was 70–80%. Participating medical prac-
titioners analyzed their patient records to identify individuals with an
established (past or current) diagnosis of a pituitary adenoma.
Patients were contacted to inform them of the study and the anon-
ymous nature of data gathering and to confirm their eligibility (living
and residing in one of the three study areas). Individual patient char-
acteristics including data on demographics, residence, diagnosis, date of
diagnosis, therapy, and site of hospital treatment were recorded on the
case report form. Thereafter in each case further definitive information
establishing the diagnosis of a pituitary adenoma was sought from
hospital case files or other relevant clinical records. Patients with other
pituitary conditions like craniopharyngioma or inflammatory lesions
were excluded. In all cases, the primary clinical signs/symptoms at
presentation (maximum of three), radiological imaging studies of the
pituitary region, and hormonal profiles demonstrating relevant disor-
dered secretion had to be available. In cases in which surgery was
performed, operative findings and pathological reports were sought.
Patient follow-up data (treatment and disease control) also had to be
available in all cases; for the purpose of this study, patients were defined
as having biochemically stable disease if their hormonal levels were
controlled to a level at which hormonal hypersecretion symptoms were
not evident. In the case of patients with acromegaly, IGF-I had to be
controlled to within the normal ranges for age and sex. Furthermore,
patients with hypopituitarism were required to have evidence of ade-
quate dosing with hormonal replacement therapy before being assessed
as biochemically stable. Tumor stability was assessed in all cases, either
in terms of whole tumor size changes in nonoperated cases or tumor
remnant behavior in cases with incomplete primary resection of the
pituitary adenoma. Before being included in the final cohort, each pa-
tient’s symptom and hormonal, radiological, pathological, and fol-
low-updatawere reviewed andverified separately by two of the authors
(A.F.D. and A.B.).
Familial screening
The study had its genesis in the investigation of a series of patients
with pituitary adenomas in a valley area in one of the postal code regions
of study district I (Soiron) involving less than 5000 people. During this
initial work, the issue of family clustering was suggested; however,
investigation of patients’ family histories and genealogies revealed no
familial cases. Given the relatively close geographic distance between
the study sampling sites, in the current study, identified patients also
underwent screening for familial links to assess for clustering due to
pituitary tumor-associated syndromes such as multiple endocrine neo-
plasia-1 (MEN1) and familial isolated pituitary adenomas (FIPA) (5, 6).
Medical practitioners and patients were questioned about their knowl-
edge of other familymembers with diseases suggestive ofMEN1 and for
the presence of other family members with pituitary adenomas (Car-
ney’s complex, FIPA). Further assessments of patients’ medical records
were undertaken to rule out the presence of biochemical abnormalities
typical of MEN1.
Data analysis
Means and ranges were calculated for the following criteria for each
tumor type and the total pituitary adenoma population: age, symptom
duration before diagnosis, number of MRI/computerized tomography
(CT) scans, and maximum tumor diameter. Data on sex, the main three
symptoms at presentation, tumor characteristics (macro-/microad-
enoma, suprasellar extension, invasion), requirement for surgery, post-
operative medical therapy, and disease control (biochemical, tumor)
were collected, summarized, and tabulated for each tumor type and for
the group as a whole. The prevalence of pituitary adenomas at each of
the three sampling sites was calculated individually, and the overall
prevalence in the study was expressed as the mean ( sd; 95% confi-
dence interval) of the three individual values.
FIG. 1. Map of Belgium (A) with province of Lie`ge out-
lined (green). Detailed view of districts in the province of
Lie`ge, including the three study districts (black) and the
city of Lie`ge (red). [Adapted with permission from the In-
stitut Ge´ographique National-Belgique (www.ign.be).]
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Results
Prevalence of pituitary adenomas
A total of 68 living patients with clinically confirmed pi-
tuitary adenomas were resident in the study areas as of
September 30, 2005. The mean ( sd) prevalence across the
three study areas was 94 cases per 100,000 population (95%
confidence interval, 72.2 to 115.8 cases). This translates into
a mean of one case per 1064 individuals (95% confidence
interval, 1:864 to 1:1385). A further 30 patients who were
highlighted by the participating medical practitioners were
excluded for the following reasons: deceased before cutoff
date of September 30, 2005 (n  10); mild hormonal abnor-
malities (predominantly hyperprolactinemia) without veri-
fiable evidence of a tumor on MRI (n  9); resident outside
the geographical limits of the study sites (n  7); cranio-
pharyngioma (n  2) and arachnoid cyst (n  2).
Demographics
The summary details of the individual patients are shown
in Table 1. The group of patients with verified pituitary
adenomas consisted of 22males and 46 females. Twopatients
were of North African origin; the rest were Caucasian. The
mean age at diagnosis was 40.3 yr (range 12–86 yr), and
patients on average had suffered symptoms attributable to
their diagnosis for 45.3 months (range 1–300 months) before
a diagnosis was made. Patients were not uniformly distrib-
uted by age at diagnosis: 0–9 yr (n  0), 10–19 yr (n  5),
20–29 yr (n 13), 30–39 yr (n 18), 40–49 yr (n 13), 50–59
yr (n  9), 60–69 yr (n  7), 70–79 yr (n  2), 80–89 yr (n 
1), older than 90 yr (n  0).
Disease characteristics
Overall, prolactinomas were the most frequent tumor
found (45 of 68; 66.2%), followed by nonsecreting tumors (10
of 68; 14.7%), somatotropinomas (nine of 68; 13.2%), and
Cushing’s disease (four of 68; 5.9%). No patient in the cohort
had a tumor that secreted TSH alone, although one patient
with acromegaly had a tumor that cosecreted GH, prolactin,
and TSH, and the patient exhibited signs/symptoms of hy-
perthyroidism in addition to acromegaly. Familial links
among patients were not found in this cohort, and only one
patient (a female with a macroprolactinoma) had sporadic
MEN1 that had been confirmed by genetic screening.
Radiological diagnosis and follow-up were performed us-
ing MRI of the pituitary (3-mm cuts) in 56 patients. The
remaining 12 patients had tomography or CT at diagnosis,
and nine of these 12 patients subsequently had their tumor
characteristics confirmed during surgery. MRI was used for
long-term follow-up in all patients originally diagnosed us-
ing tomograms and CT. The mean number of MRI and CT
scans per patient during their diagnosis and follow-up was
4.9 (range 1 to 16 scans). All 68 patients had valid radiological
results to determine the presence of a macroadenoma (n 
29) or a microadenoma (n  39); the mean maximal tumor
diameter was 12.9 mm (range: 2–50 mm) for the group over-
all. Suprasellar extension was noted in eight patients with
prolactinomas (17.8%), seven patients with nonsecreting ad-
enomas (70%), and four patients with acromegaly (44.4%).
Tumor invasion was noted in eight (17.8%), four (40%), four
(44.4%), and one patient (25%) in the prolactinoma, nonse-
creting adenoma, acromegaly, and Cushing’s disease
groups, respectively (Table 1).
Treatment and follow-up
A total of 38 patients (55.9%) underwent surgery, and the
approach was transsphenoidal in all but one patient (tran-
snasal), whereas two patients underwent repeat surgery.
Pathological results were available in 34 of 38 operated cases
(89.5%), and in all cases tumorswere benign adenomas. Only
two patients received radiotherapy: the patient with MEN1
whose macroprolactinoma was resistant to surgery and do-
pamine agonists and a second patientwith Cushing’s disease
and residual tumor postoperatively. Hypopituitarism was
present at diagnosis in eight patients, all of whom had non-
secreting adenomas. Postoperatively, seven of these patients
still had hypopituitarism, along with six patients with pro-
lactinoma and one with acromegaly.
As noted above, prolactinomas were the most frequent
tumors encountered in the current study (66.2%), and ap-
proximately 80% were microprolactinomas that occurred in
females. The most frequent presenting symptoms in these
cases were oligo or amenorrhea in two thirds of cases, fol-
lowed by galactorrhea and headache in about 50% of cases
each. As shown in Table 1, dopamine agonists were used in
39 of 45 patients with prolactinomas, 26 of whom did not
have surgery. Of the 19 patients (12 female) who underwent
surgery, nine patients hadmacroadenomas. Among prolacti-
nomas, biochemical control was achieved in all but four
cases, and tumor size remained stable during subsequent
dopamine agonist therapy. Three of these patients had mac-
roadenomas, two ofwhomweremaleswith invasive tumors.
Eight of the nine patients with acromegaly underwent sur-
gery (one twice); long-termmedical therapy with somatosta-
tin analogs was used in four cases. Only one patient with
acromegaly failed to achieve adequate long-term biochem-
ical control; this patient was intolerant to both somatostatin
analogs and pegvisomant postoperatively. Seven patients
with nonsecreting adenomas underwent surgery. As noted
above, one patient with Cushing’s disease had persistent
biochemically active disease despite surgery and therefore
required radiotherapy; the patient remains hormonally con-
trolled and without hypopituitarism at this time.
Discussion
In this cross-sectional study, we found that verified, clin-
ically relevant pituitary adenomas occurred with a preva-
lence of 1:1064 of the population, which is notably higher
than previous data would suggest. This is the first cross-
sectional study of pituitary adenomas to involve an intensive
case-finding approach at a community level involving not
only endocrinologists but also general practitioners and
other medical specialists. This approach was intended to
maximize the identification of relevant caseswithin the study
districts irrespective of the site ormanner inwhich theywere
followed up clinically.
Specific epidemiological studies regarding clinically active
pituitary adenomas are relatively scarce. Most available in-
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1 I M 19 12 Increased PRL, TRH test 20
2 I F 33 5 Increased PRL, TRH test 3.5
3 I M 61 36 Increased PRL, TRH test 20
4 I F 42 36 Increased PRL, TRH test 15
5 I M 48 N/A Increased PRL 27
6 I F 47 24 Increased PRL, TRH test 6
7 I F 21 24 Increased PRL,  TRH test 6
8 I F 50 N/A Increased PRL 4
9 II M 38 90 Increased PRL, TRH test 7
10 II F 33 18 Increased PRL N/A
11 II F 23 60 Increased PRL, TRH test 8
12 II F 24 54 Increased PRL, TRH test 7.5
13 II F 36 24 Increased PRL, TRH test 5
14 II F 28 42 Increased PRL, TRH test 6
15 II F 51 18 Increased PRL, TRH test 9
16 II F 24 36 Increased PRL, TRH test 6
17 II M 12 12 Increased PRL, TRH test 8
18 II F 32 6 Increased PRL, TRH test 9
19 II F 53 N/A Increased PRL, TRH test N/A
20 II M 31 N/A Increased PRL, TRH test 5
21 II F 35 144 Increased PRL, TRH test 10
22 II F 28 12 Increased PRL, TRH test 4
23 II M 39 1 Increased PRL, TRH test 20
24 II F 54 N/A Increased PRL 35
25 II F 52 6 Increased PRL, TRH test 25
26 II M 54 Increased PRL 5
27 II F 42 N/A Increased PRL N/A
28 II F 42 N/A Increased PRL 4
29 II F 21 12 Increased PRL 5
30 II F 45 N/A Increased PRL 4
31 II F 40 12 Increased PRL, TRH test 7
32 III F 23 72 Increased PRL, TRH test 20
33 III F 26 12 Increased PRL, TRH test 5
34 III F 32 180 Increased PRL, TRH test N/A
35 III F 27 6 Increased PRL, TRH test 9
36 III F 40 216 Increased PRL, TRH test N/A
37 III F 26 1 Increased PRL, TRH test 20
38 III F 28 36 Increased PRL, TRH test 5
39 III F 45 120 Increased PRL, TRH test 3
40 III F 15 N/A Increased PRL, TRH test 5
41 III M 30 12 Increased PRL, TRH test 5
42 III F 30 6 Increased PRL, TRH test 4
43 III F 37 18 Increased PRL, TRH test 5
44 III F 35 N/A Increased PRL 3
45 III F 25 12 Increased PRL, TRH test 2
Somatotropinomas
46 I M 35 12 Increased IGF-I, GH, OGTT 11
47 I M 47 180 Increased GH, IGF-I, OGTT 13
48 I M 60 300 Increased GH, IGF-I 36
49 II M 19 60 Increased GH, PRL, TSH, OGTT 15
50 II M 32 72 Increased GH, IGF-I, OGTT 30
51 III F 63 20 Increased GH, OGTT 14
52 III F 17 36 Increased GH, OGTT N/A
53 III F 56 60 Increased GH, IGF-I, OGTT 28
54 III M 65 48 Increased GH, IGF-I, OGTT 15
Nonsecreting adenomas
55 I M 50 12 Low LH/FSH/GH, ITT 15
56 I F 77 24 Low LH/FSH, TRH/LHRH test 35
57 I M 76 4 Low LH, low Tes 20
58 II F 42 24 No pituitary hormone abnormality 5
59 III M 49 4 Panhypopituitarism, TRH/LHRH test 19
60 III M 69 36 High LH/FSH 23
61 III M 86 1 Low LH, low IGF-I 50
62 III M 61 12 Low Tes/IGF-I, ITT 35
63 III M 62 24 Low Tes 14
64 III F 41 120 Low LH/FSH, low Est 10
Cushing’s disease
65 I F 55 120 Increased ACTH,  including 24-h dexamethasone suppression test 5
66 I F 30 N/A Increased ACTH,  24 h urinary cortisol 5
67 II F 37 24 Increased ACTH,  24 h urinary cortisol N/A
68 III F 36 24 Increased cortisol,  24 h urinary cortisol,  dexamethasone suppression test 12
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TABLE 1. Continued








Macro Yes Yes TS CAB, Tes, GH No Yes
Micro No No No CAB Yes Yes
Macro Yes Yes TS CAB, HC, Tes, GH Yes Yes
Macro Yes No TS CAB Yes Yes
Macro No Yes TS CAB No Yes
Micro No No No BR Yes Yes
Micro No No TS CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No Yes TS CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No TS Yes Yes
Micro No No TS Yes Yes
Micro No No TS CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No TS Yes Yes
Micro No No TS Yes Yes
Micro No No TS CAB, Thy, HC Yes Yes
Micro No Yes No CAB Yes Yes
Micro No No No CAB Yes Yes
Macro No Yes No CAB No Yes
Micro No No TS Yes Yes
Macro Yes Yes TS CAB, Tes, GH Yes Yes
Macro Yes Yes TS Radiotherapy CAB, Thy, HC Yes Yes
Macro Yes No TS CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No BR Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Macro Yes No No CAB Yes Yes
Micro No No TS Yes Yes
Macro No No TS BR Yes Yes
Micro No No No CAB Yes Yes
Micro No No No BR Yes Yes
Macro Yes No TS CAB, Thy, HC, Est Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No BR No Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Micro No No No CAB Yes Yes
Macro No No TS Yes Yes
Macro No No TS LAN Yes Yes
Macro No Yes TS LAN Yes Yes
Macro Yes Yes TS ( 2) Yes Yes
Macro Yes Yes No LAN Yes Yes
Macro No No TS No
Micro No No TS Thy, Est, GH Yes Yes
Macro Yes Yes TS OCT Yes Yes
Macro Yes No TS Yes Yes
Macro No No No Thy, HC Yes Yes
Macro Yes Yes TS CAB, Thy, HC, Yes Yes
Macro Yes Yes TS Yes Yes
Micro No No No Yes Yes
Macro Yes No TS Thy, HC, Tes, GH Yes Yes
Macro Yes No TS Yes Yes
Macro Yes No TS Thy, HC Yes Yes
Macro Yes Yes TS Thy, HC, Tes, GH Yes Yes
Macro No Yes No Tes Yes Yes
Macro Yes No TN HC Yes Yes
Micro No No TS Yes Yes
Micro No No TS Radiotherapy Yes Yes
Micro No No TS Yes Yes
Macro No Yes TS ( 2) Yes Yes
Data are divided as per tumor phenotype and then listed in order of study district. Biochemical control was defined as a hormonal level at
which patients’ symptoms were kept at bay; whereas in the case of acromegaly, patients had to have an IGF-I level in the normal range for
age and sex to be considered controlled. N/A, Not available; BR, bromocriptine; CAB, cabergoline, Est, estrogen, HC, hydrocortisone, ITT, insulin
tolerance test, LAN, lanreotide, OCT, octreotide, OGTT, oral glucose tolerance test, PRL, prolactin, Tes, testosterone; Thy, thyroxine; TN,
transnasal; TS, transsphenoidal.
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formation comes from larger cancer registries, in which data
on pituitary adenomas are reported as a subgroup of all brain
or central nervous system tumors. Such registry data reveal
that pituitary adenomas comprise approximately 5–20% of
primary central nervous system tumors, which would trans-
late into a relatively low prevalence of pituitary adenomas
(7). In contrast, data from autopsy series or MRI studies of
unselected populations indicate that the presence of a pitu-
itary tumor, irrespective of clinical correlates, is relatively
common. In their recentmetaanalysis, Ezzat et al. (2) reported
that pituitary adenomas occurred with a frequency of 14.4%
(range: 1–35%) and 22.5% (range: 1–40%) in pooled autopsy
and radiological series, respectively. Of autopsy specimens
that underwent immunohistochemical analysis, 25–41% of
cells were prolactin positive, with much more infrequent
staining for other pituitary hormones (0.7–4.9%).
These interesting data suggest that a proportion of cases
found at autopsy may represent undiagnosed clinically rel-
evant pituitary tumors. The metaanalytic data need to be
balanced against the small size of the database from which
prevalence data were derived; the autopsy population in-
cluded 3375 patients, and the radiology series comprised 202
individuals. Autopsy/radiology estimates do not include
clinical correlates, such as symptoms and hormonal data,
whereas the current study included clinically relevant pitu-
itary adenomas that had already been diagnosed. The study
was not designed to screen for either occult pituitary ade-
nomas with relevant, albeit undiagnosed, clinical effects or
pituitary incidentalomas that lacked clinical correlates.
Therefore, the current study may underestimate the true
prevalence of pituitary adenomas in the general population.
It remains practically difficult to estimate what proportion of
incidentally discovered autopsy cases, particularly microad-
enomas, have objective hormonal abnormalities or signifi-
cant symptomatology. We would suggest, however, that the
inclusion of true incidentalomas into prevalence estimates
does not aid the assessment of the clinical burden attributable
to pituitary adenomas in the general population.
Current estimates of brain cancer epidemiology from the
Central Brain Tumor Registry of the United States suggests
a prevalence of 130.8 cases per 100,000 population (1, 8). Data
from 2005 in Finland reported an even higher prevalence of
primary brain tumors, with a prevalence rate of 228 cases per
100,000 (9). With respect to the Central Brain Tumor Registry
of theUnited States data, Davis et al. (1) estimated that benign
tumor cases constitute 97.5 cases per 100,000, a largemajority
of the total prevalence. These benign cases are comprised of
meningiomas and other histological types in addition to pi-
tuitary adenomas, so a precise estimate of the prevalence of
the latter alone is not readily feasible. The proportional in-
cidence rates of pituitary tumors, 7.2% of primary brain
tumors by site and 6.3% by histology, is not particularly
helpful in estimating prevalence (8). The low associatedmor-
tality in pituitary adenomas would lead to a higher elevated
prevalence rate during long-term follow-up as compared
with other brain tumors that have a higher annual incidence
rate but a concomitantly high 1- to 5-yr mortality rate.
As noted by Monson (10), the indolent nature of many
endocrine tumors, the patterns of clinical care among various
specialties, and the lack of a relationship between incidence
and mortality may mitigate against obtaining accurate epi-
demiological data on endocrine tumors. These factors are
particularly true in the case of pituitary adenomas. Histor-
ically, benign brain tumors, such as pituitary adenomas, have
been underreported in cancer registries due to a lack of
legally obligated reporting (1, 11). This will change in the
future with greater emphasis being placed on nonmalignant
tumors; in the United States, the passage of the Benign Brain
Tumor Cancer Registries Amendment Act means that new
cases of pituitary adenomas have been reportable since Jan-
uary 1, 2004 (12). It will therefore be some years before
comprehensive data on pituitary adenoma incidence and
prevalence are available from major cancer registries.
Few studies specifically examining the epidemiology of
pituitary adenomas have been undertaken. In a study of the
Stoke-on-Trent region in the United Kingdom between 1988
and 1998, Davis et al. (13) reported that pituitary adenomas
occurred with a prevalence of 190–280 cases/million (1:3571
to 1:5263). In that study, patients investigated by an endo-
crinologist were included whether or not they had surgery.
It is not clear, however, whether the study captured all pa-
tients with pituitary adenomas resident in the region that
may have received treatment outside the geographical
boundaries. Our study reported a prevalence rate of 3.4–5
times that of Davis et al., and this may have been due, in part,
to our being able to identify and verify patientswith pituitary
adenomasmore completely in amore tightly controlled pop-
ulation.Nilsson et al. (3) studied incidence andmortality data
in a Swedish Cancer Registry study. This study, which ex-
cluded patients with acromegaly and Cushing’s disease, re-
ported an incidence of 11 cases/million population per year
during a period up to 1991. This constituted nearly a dou-
bling in annual incidence in comparison with previous data
from 1958. It is unknown whether this apparent rise in in-
cidencewas due to the advent of better diagnostic techniques
or a true increase in incidence. Widespread access to both
MRI and laboratory techniques may have had an important
impact on the ability to diagnose pituitary adenomas that are
associated with subtle signs and symptoms. Also, patients
may be more likely than before to seek medical attention
earlier for more insidious symptoms associated with pitu-
itary adenomas, such as disorders of libido, sexual dysfunc-
tion, and infertility. Importantly, as therapies have im-
proved, the life span of patients with pituitary tumors has
also undoubtedly lengthened, which would tend to increase
the prevalence of pituitary tumors in the population. We
would suggest that the high prevalence of pituitary adeno-
mas seen in the current study may be due to such a combi-
nation of these factors.
As compared with large cancer registries that assess data
on millions of patients, the current study population may
appear limited in size. However, the aim of the study was to
identify pituitary tumors in alliance with community med-
ical practitioners and report on only those with verifiable
hormonal, radiological, and clinical profiles. We undertook
an intensive process of identifying, recruiting, and informing
the entirety of the medical population of the chosen study
sites, followed by a similar process of identifying, validating,
and recruiting potential patients. Given these requirements
and the parallel process of data validation in all cases, a
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population of approximately 72,000 approached the maxi-
mum feasible for an academic cross-sectional study. Further
confirmation of these results will require international co-
operative efforts using new or existing data-gathering and
epidemiological tools.
We considered the question of clustering of cases within
the study regions and the effect that might have on our
estimates. Few or no data exist on the potential impact of
race, socioeconomic status, age, and environmental factors
on the development of pituitary adenomas. We did, how-
ever, verify that known inherited factors did not influence
the data, using a combination of family history data and
genetic studies (14). Only one patient, a female with a rela-
tively treatment-resistant macroprolactinoma, had MEN1,
and this was a sporadic case with no other relatives forming
part of the study population. Carney’s complex is very rare
andwas not a feature of the patientswith somatotropinomas.
Of potentially greater relevance is the syndrome of FIPA,
which may be linked to mutations in the aryl hydrocarbon
receptor interacting protein (6, 15). The patients included in
the current study did not have known relatives with a di-
agnosis of pituitary tumors, making the influence of FIPA in
this population unlikely. The role of specific environmental
factors such as carcinogen exposure in the etiology of pitu-
itary adenomas requires further assessment, particularly be-
cause the aryl hydrocarbon receptor, for which aryl hydro-
carbon receptor interacting protein is a ligand, mediates cell
responses to toxins such as dioxin (16).
In the current study, prolactinomas comprised 66% of the
entire series, of which the majority were microadenomas in
female patients (80%) that presented classically with either
oligo/amenorrhea, galactorrhea, or headache. This is in
keeping with previous data from surgical series and immu-
nohistochemical studies of autopsy data (13, 17, 18). Despite
the fact that the majority of prolactinomas were small, the
attendant use of health care resources appears sizable, given
the performance of multiple MRI/CT scans, dynamic pitu-
itary function tests, and the frequent requirement formedical
or surgical therapy. The management of other tumor types
requires even greater resource use than for prolactinomas.
High health care resource use in the setting of a much in-
creased prevalence of pituitary adenomas represents an im-
portant issue for calculating medical and research budgets,
although confirmation in formal pharmacoeconomic studies
is required.
In conclusion, the current cross-sectional study indicates
that clinically active pituitary adenomas occur relatively fre-
quently in the general population. In contrast to autopsy and
radiological studies, the current study included only patients
that had a previous definitive diagnosis of a pituitary ade-
noma. The historical lack of mandatory reporting of benign
brain tumors may have led to an underestimation of the
prevalence of pituitary adenomas in large cancer registries.
In the absence of registry data, larger cooperative studies
using a similar intensive case finding approach to ours and
involving diverse population samples from multiple centers
could help to provide further information on the true prev-
alence of pituitary adenomas internationally.
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